Increasing incidence of pertussis in Brazil: a retrospective study using surveillance data

BMC Infectious Diseases

Filipe Anibal Carvalho-Costa²  Eduilson Lívio Neves da Costa Carneiro¹  Lucas Melo Guimarães² 

[1] Federal Institute of Education, Science and Technology of Piauí (IFPI), Teresina, Piauí, Brazil;Laboratory of Epidemiology and Molecular Systematics, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil

关键词: Brazil;    Vaccination;    Epidemiology;    Bordetella pertussis;    Pertussis;   

Others  :  1232907
DOI  :  10.1186/s12879-015-1222-3

 received in 2015-07-22, accepted in 2015-10-15,  发布年份 2015

【 摘 要 】

Background

Many countries have reported an increase in the incidence of pertussis, which has become a global public health concern.

Methods

In this study, the epidemiology of pertussis in Brazil was assessed retrospectively using surveillance data gathered from case notification forms from 2007 to 2014.

Results

From 2007 to 2014, 80,068 suspected cases of pertussis were reported in Brazil. Of these, 24,612 (32 %) were confirmed by various criteria. The annual distribution of confirmed cases demonstrated a significant increase in incidence rate since 2012. A seasonal pattern in which cases occur most frequently between the end of spring and midsummer has been identified. Among the confirmed cases, 34.5 % occurred in infants aged 0–2 months, 22.4 % occurred in infants aged 3–6 months, 21 % occurred in children aged 7 months to 4 years, and 8 % were reported in adults >21 years. Of the confirmed cases, 47.2 % met only clinical criteria, 15.5 % met clinical and epidemiological criteria, and 36.6 % were confirmed in a laboratory. The overall case fatality rate was 2.1 %, reaching 4.7 % among infants aged 0–2 months. The complications most commonly reported in the notification forms were pneumonia, encephalitis, dehydration, otitis, and malnutrition. Of the confirmed cases, 23.1 % occurred in subjects who received at least 3 doses of the pertussis vaccine. Within this group, there were 1098 infants aged 7 to 15 months and 2079 children aged 16 months to 4 years. In 2012, 18 states did not achieve 95 % immunization coverage, a number that dropped to 10 and 6 in 2013 and 2014, respectively.

Conclusions

Brazil’s main challenges in facing pertussis resurgence will be to offer the best quality medical attention to reduce mortality, to improve the infrastructure for laboratory diagnosis and to increase vaccination coverage. Additional studies to assess the effectiveness of the current vaccination schedule and basic research on the genetics and evolution of circulating B. pertussis strains are also needed.

【 授权许可】

   
2015 Guimarães et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 8.

Fig. 9.

【 参考文献 】

• [1]Berti E, Chiappini E, Orlandini E, Galli L, de Martino M. Pertussis is still common in a highly vaccinated infant population. Acta Paediatr. 2014; 103(8):846-849.
• [2]Winter K, Glaser C, Watt J, Harriman K. Pertussis epidemic--California, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(48):1129-1132.
• [3]Tizolova A, Brun D, Guiso N, Guillot S. Development of real-time PCR assay for differential detection of Bordetella bronchiseptica and Bordetella parapertussis. Diagn Microbiol Infect Dis. 2014; 78(4):347-351.
• [4]Leber AL. Pertussis: relevant species and diagnostic update. Clin Lab Med. 2014; 34(2):237-255.
• [5]Ferrer A, Calicó I, Manresa JM, Andreu A, Moraga F, Valle I. Microorganisms isolated in cases of pertussis-like syndrome. Enferm Infecc Microbiol Clin. 2000; 18(9):433-438.
• [6]Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005; 18(2):326-382.
• [7]Jakinovich A, Sood SK. Pertussis: still a cause of death, seven decades into vaccination. Curr Opin Pediatr. 2014; 26(5):597-604.
• [8]Chiappini E, Stival A, Galli L, de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis. 2013; 13:151. BioMed Central Full Text
• [9]Galindo BM, Concepción D, Galindo MA, Pérez A, Saiz J. Vaccine-related adverse events in Cuban children, 1999–2008. MEDICC Rev. 2012; 14(1):38-43.
• [10]Lambert LC. Pertussis vaccine trials in the 1990s. J Infect Dis. 2014; 209 Suppl 1:S4-S9.
• [11]Klein NP. Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother. 2014; 10(9):2684-2690.
• [12]Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014; 9:CD001478.
• [13]Torres RS, Santos TZ, Torres RA, Pereira VV, Fávero LA, Filho OR, Penkal ML, Araujo LS. Resurgence of pertussis at the age of vaccination: clinical, epidemiological, and molecular aspects. J Pediatr (Rio J). 2015; 91(4):333-338.
• [14]Departamento de Informações do Sistema Único de Saúde do Brasil - DATASUS [http://pni.datasus.gov.br/index.asp] Accessed 21 March 2015.
• [15]Centers for Disease Control and Prevention. Pertussis (whopping cough). Pertussis cases by year (1922 - 2014). Available in:http://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html. Accessed March 20th2015.
• [16]Pertussis epidemic--Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012; 61(28):517-522.
• [17]Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, Chavez G. California pertussis epidemic, 2010. J Pediatr. 2012; 161(6):1091-1096.
• [18]European Centre for Disease Prevention and Control. Annual epidemiological report 2014 – Vaccinepreventablediseases – invasive bacterial diseases. Stockholm: ECDC; 2015.
• [19]EUVAC.NET. Pertussis surveillance report 2003 - 2007. Available in: http://ecdc.europa.eu/en/publications/Publications/pertussis_report_2003_2007_euvacnet.pdf. Accessed 19 March 2015.
• [20]EUVAC.NET. Pertussis surveillance report 2009. Available in: http://www.euvac.net/graphics/euvac/pdf/pertussis_2009.pdf. Accessed 19 March 2015.
• [21]de Melker HE, Conyn-van Spaendonck MA, Rümke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis. 1997; 3(2):175-178.
• [22]Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005; 24(6 Suppl):S104-S108.
• [23]Shaikh R, Guris D, Strebel PM, Wharton M. Underreporting of pertussis deaths in the United States: need for improved surveillance. Pediatrics. 1998; 101(2):323.
• [24]Sutter RW, Cochi SL. Pertussis hospitalizations and mortality in the United States, 1985–1988. Evaluation of the completeness of national reporting. JAMA. 1992; 267(3):386-391.
• [25]Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995-2005--trends by region and age group. Commun Dis Intell Q Rep. 2007; 31(2):205-215.
• [26]Pérez-Pérez GF, Rojas-Mendoza T, Cabrera-Gaytán DA, Grajales-Muñizd C. Panorama epidemiológico de la tos ferina:19 años de estudio epidemiológico en el Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc. 2015; 53(2):164-170.
• [27]Sistema de Informação de Agravos de Notificação - SINAN [http://dtr2004.saude.gov.br/sinanweb/tabnet/dh?sinannet/coqueluche/bases/coquebrnet.def] 21 March 2015.
• [28]Salomão Junior JB, Gardinassi LG, Simas PV, Bittar CO, Souza FP, Rahal P, Zanetta DM. Human respiratory syncytial virus in children hospitalized for acute lower respiratory infection. J Pediatr (Rio J). 2011; 87(3):219-224.
• [29]Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health. 2012; 9(12):4626-4638.
• [30]de Carvalho AP, Pereira EM. Acellular pertussis vaccine for adolescents. J Pediatr (Rio J). 2006; 82(3 Suppl):S15-S24.
• [31]Schellekens J, von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J. 2005; 24(5 Suppl):S19-S24.
• [32]Hay JW, Ward JI. Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005; 24(6 Suppl):S127-S133.
• [33]Spokes PJ, Quinn HE, McAnulty JM. Review of the 2008–2009 pertussis epidemic in NSW: notifications and hospitalisations. N S W Public Health Bull. 2010; 21(7–8):167-173.
• [34]Pardo-Serrano FJ. Situation of pertussis in the community of Valencia: an epidemic revival? Enferm Infecc Microbiol Clin. 2014; 32(4):270-271.
• [35]Faulkner A, Skoff T, Martin S, Cassiday P, Tondella ML, Liang J, Ejigiri OG: Manual for surveillance of vaccine-preventable diseases. Chapter 10: Pertussis. Available in: http://www.cdc.gov/vaccines/pubs/survmanual/chpt10-pertussis.html. Accessed 19 March 2015.
• [36]Borisova O, Kombarova SY, Zakharova NS, van Gent M, Aleshkin VA, Mazurova I, Mooi FR. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol. 2007; 14(3):234-238.
• [37]Halperin SA, Wang EE, Law B, Mills E, Morris R, Déry P, Lebel M, MacDonald N, Jadavji T, Vaudry W et al.. Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis. 1999; 28(6):1238-1243.
• [38]Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. Pediatrics. 1999; 104(4):e42.
• [39]van Hoek AJ, Campbell H, Amirthalingam G, Andrews N, Miller E. The number of deaths among infants under one year of age in England with pertussis: results of a capture/recapture analysis for the period 2001 to 2011. Euro Surveill. 2013;18(9). Available in: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20414. Accessed 23 March 2015.
• [40]Centers for Disease Control and Prevention. 2013 Final Pertussis Surveillance Report. Available in: http://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2013.pdf. Accessed 19 March 2015.